EPISODE · Nov 11, 2010 · 31 MIN
A Closer Look at Egrifta, a Newly Approved Treatment for HIV-Associated Belly Fat Gain (Lipohypertrophy)
from This Month in HIV
On Nov. 10, Egrifta (tesamorelin) became the first drug approved in the U.S. to treat unusual fat gain, or lipohypertrophy, in people with HIV. In our latest episode of This Month in HIV, we talk with noted HIV researcher Daniel Berger, M.D., about how Egrifta works, who should take it, and what else we know to date about the treatment of lipohypertrophy.
NOW PLAYING
A Closer Look at Egrifta, a Newly Approved Treatment for HIV-Associated Belly Fat Gain (Lipohypertrophy)
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m